Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Numerous studies in many tumor types have demonstrated that quantitation by microvessel as a measure of angiogenesis is a powerful prognostic tool. However, the ability to exploit tumor angiogenesis as a prognostic marker is limited by the methods currently used for capillary identification and quantitation. This report critically evaluates all aspects of the techniques and their associated problems used for assessing tumor angiogenesis in tissue sections including the area of tumor assessed, the vascular parameter measured, the method of quantitation, the stratification of patients and the practical utility of computer image analysis systems. The potential of angiogenic factors assays, proteolytic enzymes, and cell adhesion molecules as surrogate endpoints for quantifying tumor angiogenesis are discussed and other methods for quantifying tumor angiogenesis are described. The potential clinical applications of these angiogenic markers in prognosis, stratification for adjuvant treatments (both cytotoxic and anti-angiogenic/vascular targeting) and other aspects of patient management is also discussed, particularly design of phase I and II trials.

Original publication

DOI

10.1023/a:1005714527315

Type

Journal article

Journal

Invest New Drugs

Publication Date

1997

Volume

15

Pages

15 - 28

Keywords

Antibodies, Antigen-Antibody Reactions, Antineoplastic Agents, Biomarkers, Tumor, Cell Adhesion Molecules, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Drugs, Investigational, Humans, Image Processing, Computer-Assisted, Neoplasms, Neovascularization, Pathologic, Peptide Hydrolases, Prognosis, Randomized Controlled Trials as Topic